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and David Hogg8
Melanoma is the most dangerous of all common skin cancers, due to its propensity to metastasize. Therefore,
identification of at-risk populations may allow early detection of disease at a curable stage. In Europe and North
America, between 8–14% of melanoma patients have a family history of the disease, and a subset of these
individuals possess germline mutations in the CDKN2A gene, which encodes the p16INK4A and p14ARF tumor
suppressors. We identified 30 patients (29 families) from Southern Brazil, who had a family history of melanoma
and/or pancreatic cancer; or a personal history of multiple primary melanoma. We screened this cohort for
mutations in the CDKN2A and CDK4 genes, and detected two functional mutations: a G-34T transversion in
50untranslated region; and a M53I alteration encoded in exon 2. Both mutants have been previously associated
with melanoma and demonstrate founder effects. We conclude that germline mutations of CDKN2A occur in
the Brazilian population, and that these mutations likely originated in Europe.
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INTRODUCTION
Cutaneous malignant melanoma (CMM) accounts for ap-
proximately 1% of all malignant tumors, but is the leading
cause of death from skin cancer, due to its propensity to
metastasize. The incidence of CMM has increased drama-
tically over the past five decades worldwide (Berwick and
Halpern, 1997). Several risk factors for the development of
CMM have been identified. Ethnic origin is particularly
important: CMM is largely a disease of European populations.
Within susceptible populations, individual cutaneous and
pigmentary characteristics increase melanoma risk. These
include the presence of multiple nevi, atypical or dysplastic
nevi, freckles, red hair, skin that does not acquire a tanned
color (phototype I); and a history of sunburns (Bressac-de-
Paillerets et al., 2002). Several epidemiologic studies have
demonstrated that sun exposure, particularly in infancy, is a
major environmental cause of melanoma, and that up to 65%
of all melanoma cases are related to sunburns (Armstrong and
Kricker, 1993; Whiteman et al., 2001). In a case–control
study in Southern Brazil, Bakos et al. (2002) found a 2.7-fold
increase in the risk for melanoma in individuals with
phototypes I/II compared with those with phototypes III/IV.
The same study showed that the number of nevi (430) and
the presence of dysplastic nevi were moderate risk factors,
and that a past history of multiple sunburns was the single
most important risk factor.
In Brazil, an estimated 6,000 new cases of CMM are
diagnosed each year, and this number may be even higher if
underreporting is considered. The three southernmost states
of the country are located between parallels 341S and 221N
and have the largest proportion of individuals of Northern-
European ancestry. They also have the highest incidence rates
of CMM. A few studies have investigated environmental risk
factors for CMM in this region and showed that (a) the region
has the highest proportion of fair-skinned individuals in the
country; (b) it receives nearly 10% more UV radiation than
the corresponding northern latitudes and receives the highest
global concentrations of UVA during the summer months
(Diffey and Elwood, 1994), and; (c) most individuals,
especially children and adolescents, have an intense
exposure to sun during certain periods of the year (summer
months), without adequate photoprotection (Angeli et al.,
1997). This behavior is further evidenced by the high
frequency of sunburns, across age groups (Bakos et al., 2002).
Approximately 8–14% of patients with CMM have a
positive family history of the disease (Grange et al., 1995).
The presence of more than one case of melanoma in a family
may occur by chance alone, or may be due to low
penetrance alleles and/or sun exposure habits common to
affected relatives. However, an estimated 25% of familial
melanoma is associated with germline mutations of the
CDKN2A gene, and often presents with an autosomal
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dominant pattern of transmission (Greene, 1999). Most of
these mutations affect the p16INK4A tumor suppressor
product, encoded by exons 1a, 2, and 3 of CDKN2A (Hogg,
1998). In addition,B9% of individuals with multiple primary
melanomas, but who lack any family history of CMM, will
have a germline mutation of CDKN2A (Monzon et al., 1998;
Puig et al., 2005, and unpublished data). Mutations of
CDKN2A/p16INK4A also predispose to pancreatic carcinoma,
albeit at a lower frequency than melanoma (Lynch and
Fusaro, 1991; Goldstein et al., 1995). In keeping with other
inherited cancer syndromes, individuals bearing germline
CDKN2A mutations typically present at an early age of onset
compared to sporadic cases (36 vs 57 years for men and 29 vs
50 years for women) (Greene, 1999).
The penetrance of CDKN2A germline mutations is a
subject of current debate. The Melanoma Genetic Con-
sortium (GenoMel) studied melanoma-prone families and
suggested that the penetrance by age 80 ranges from 0.58 to
0.91, subject to geographic/latitudinal variation, presumably
on the basis of UV exposure (Bishop et al., 2002). In contrast,
Begg et al. (2005) identified unselected melanoma patients
bearing CDKN2A mutations and ascertained the lifetime risk
in first degree relatives using a kin–cohort method. They
calculated the penetrance at age 80 to be only 0.28. It is
possible that other risk alleles, such as MC1R or OCA2
variants (Kennedy et al., 2001; Duffy et al., 2004; Goldstein
et al., 2005), are enriched in large melanoma kindreds, such
as those identified by GenoMel.
A small number of melanoma-prone families bear muta-
tions in CDKN2A that alter p14ARF, encoded by exons 1b, 2,
and 3 (Quelle et al., 1995), which often occur at the splice
donor site of exon 1b (Harland et al., 2005). Individuals
bearing such mutations may also be predisposed to central
and peripheral nervous system tumors. Rare families possess
mutations of the CDK4 gene (Greene, 1999), which encodes
the cell cycle kinase CDK4, targeted by p16INK4A. Finally,
mutations in other tumor suppressor genes such as BRCA2
and NF1 are also associated with a moderately increased risk
of melanoma (Andersen et al., 1993; Neuhausen et al., 1998).
Most CMM diagnosed at an early stage are surgically
curable. In advanced stages, however, mortality rates remain
high even after aggressive therapeutic interventions. Therefore,
the identification of genetically predisposed individuals may be
important to assure proper referral and to optimize screening
and early diagnosis in this high-risk group (Hansen et al., 2004).
Although previous studies have shown significant evidence
for environmental risk factors as the cause for the high incidence
rates of melanoma in Southern Brazil, a contribution of genetic
risk factors cannot be excluded. This study was conducted to
identify the clinical and molecular features in a group of
individuals at risk for hereditary melanoma in Southern Brazil.
RESULTS
Thirty-five individuals fulfilling at least one of the inclusion
criteria were identified in public or private dermatology
clinics in Porto Alegre, Brazil’s southernmost capital. Of
these, 30 patients from 29 families decided to participate in
the study. Patient characteristics are summarized in Table 1.
None of the patients fulfilled criteria for diagnosis of the
dysplastic nevus syndrome. The majority were female, a
significant proportion (20/30) had very fair skin (phototype 1),
and most had melanoma in sun-exposed body areas and
reported a past history of multiple sunburns (i.e., from a total
number of 49 melanomas in 30 patients, only four were
diagnosed in sun-unexposed body areas). No proband had
Table 1. Clinical characteristics of the 30 patients
included in this study
Index cases (n=30)
Variable
frequencies (*)
CDKN2A
genotype1
(mutation
positive)
Gender (female) 19 (63.3)
Phototype I 20 (66.7)
Past history of sunburn(s) 24 (80.0)
CMM in area unexposed to sun 4 (13.3)
Age at CMM diagnosis2 49.5713.4
Number of primary CMM 1 15 (50.0)
2 11 (36.7)
3 4 (13.3)
Predicted CDKN2A mutation
probability3
0.02 (0.01–0.03)
Inclusion criteria1
(1) Multiple primary CMM
regardless of FH
15 (50.0) 2/15
(2) X2 CMM in family 12 (40.0) 2/12
(3) X2 CMM+PC in family 8 (26.7)
Families (n=29)
Age at CMM diagnosis4 50.9712.3
Number of individuals
diagnosed with CMMs and/or
PC per family5,6 1 6 (20.7)
2 16 (55.2)
X3 7 (24.1)
Number of CMM and/or
PC diagnoses per family 2 16 (55.2)
X3 13 (44.8)
CMM, cutaneous malignant melanoma; PC, pancreatic cancer.
(*) categoric variables are expressed in N (%) and quantitative variables,
as mean7SD, if symmetric, or median (interquartilic range) if asymmetric
1Same patient/family may fulfill more than one inclusion criterion.
2Age of first CMM in index case.
3Predicted probability in entire sample of patients obtained with
MELPREDICT.
4Data from CMM and/or CMM/PC families. Age refers to all CMM
diagnoses in a given family.
5Includes individuals with multiple primary CMM.
6Families with three or more individuals diagnosed with CMM or PC
included: (a) family no. 6: proband with three primary CMM; (b) family
no. 8: proband with two primary CMM and one relative with one CMM;
(c) family no. 9: proband with two primary CMM and one relative with
PC; (d) family no. 10: proband with three primary CMM; (e) family no. 13:
proband with CMM and two relative with PC; (f) family no. 14: proband
with CMM, one relative with PC and two additional relatives with CMM;
and (g) family no. 20: proband with CMM and two relatives with CMM.
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developed pancreatic carcinoma at the time of ascertain-
ment. Overall, the mean age at diagnosis of the first
melanoma in the group was 49.7 years (range, 24–72 years;
53.9 years in males and 47.4 years in females), and the
average number of individuals diagnosed with melanoma
and/or pancreatic cancer per family was 2.06. The predicted
probability of harboring a CDKN2A germline mutation in the
entire group of patients was less than 5%. When comparing
patients with the different inclusion criteria, no significant
difference was identified among groups regarding sex, age at
diagnosis of first CMM, number of relatives affected with
CMM, mean age at CMM diagnosis in the family, frequency
of a past history of sunburns, and frequency of CMM
localized in body areas not exposed to sun (data not shown).
CDKN2A analysis
Sequencing of the CDKN2A 50 untranslated and coding
regions revealed a deleterious mutation in two patients. The
first patient (family no. 6; Figure 1a), a female of Portuguese
origin, had multiple (3) synchronous primary melanomas at
age 59 and a positive family history (one first-degree and one
third-degree relative with CMM); the average age at
melanoma diagnosis in this family was 44 years. The
mutation identified, a G-T transversion at base 34
(G-34T), has been described previously: it creates a novel
AUG initiation codon and predicts a truncated, frame-shifted
protein of 4.0 kDa (Liu et al., 1999). The second patient
(family no. 26; Figure 1b), a female of Portuguese and English
origin, also had multiple (2) primary melanomas at age 41
and one affected second-degree relative; the average age at
melanoma diagnosis in this family was 46.5 years. In this
patient, a G-C transition at base 159 resulting in the
substitution of a methionine for an isoleucine in codon 53
(M53I) was identified. This mutation has previously been
described as a pathogenic mutation in North America,
Australia, and Europe, where it seems to be frequent in
Scottish melanoma families (Pollock et al., 1998; Lang et al.,
2005). Four patients of the 30 patients studied (13.33%) had a
common CDKN2A polymorphism, A148T (Bertram et al.,
2002; Debniak et al., 2005). Finally, one male patient of
Italian origin with multiple (3) primary CMM at ages 68 (2)
and 70 had a G-C transition at position 33. This individual
had a sister with pheochromocytoma, but no family history of
either CMM or pancreatic cancer. The 33 variant is
occasionally observed on CDKN2A sequencing, does not
co-segregate with disease in melanoma-prone kindreds, and
is thought to be a polymorphism (Soufir et al., 1998). None of
the patients had the R24H and R24C mutations in CDK4 or
exon 1b splice variants in the p14ARF gene.
DISCUSSION
The Southern region of Brazil has the highest incidence rates
of CMM in the country, and although several environmental
risk factors have been suggested as causative agents, a role for
a genetic influence in melanoma predisposition has not been
identified previously. Evidence for such an influence has
been identified in a few studies, including a descriptive
evaluation of 195 melanoma cases unselected for family
history diagnosed in a tertiary hospital of the city of Porto
Alegre that reported an earlier age at melanoma diagnosis
(55% of cases o45 years) and a history suggestive of
hereditary CMM in 16% of the cases (Carvalho et al.,
2004). However, these findings could be the result of a
potential ascertainment bias, since the sample size in this
study was relatively small and patients were recruited
through a tertiary hospital.
Clinical features of the patients in this study suggest that
environmental risk factors play a significant role in melanoma
occurrence in this region of South America, as evidenced by
the frequent history of sunburns, the small number of CMM
diagnosed in areas unexposed to sun, and the high frequency
of phototype I. Since we accepted families with only two
affected members or one individual with more than one
primary CMM without additional family history of CMM or
pancreatic cancer, the estimated overall probability of a
CDKN2A mutation in the sample was o5%. Our detection
frequency of CDKN2Amutations (2/29 probands—6.9%) was
slightly higher than predicted. Of note, both patients
harboring a CDKN2A germline mutation had multiple
primary CMM and at least one additional relative with CMM.
Both of the CDKN2A variants identified have been
previously characterized as founder mutations. One of them,
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Figure 1. Pedigrees of CDKN2A mutation-positive families. (a and b)
Pedigrees of CDKN2A mutation-positive families. Melanoma-affected
individuals are indicated by solid symbols, individuals affected with other
tumors by cross-hatched symbols, ages at tumor diagnosis are shown in
parenthesis, age at death is indicated whenever available. CMM, cutaneous
malignant melanoma; Pheo, pheochromocytoma.
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M53I, seems to have arisen in Scotland, but is observed
commonly in Northern Europe and North America. Although
this is the first report of the M53I mutation in a South
American patient, the mutation-affected patient descended
from a British family and likely shares the common Scottish
haplotype for this mutation. Finally, a significant number of
patients evaluated here had the common A148T CDKN2A
variant. This variant has been associated with an increased
risk for melanoma in some (Debniak et al., 2005), but not all
populations (Bertram et al., 2002). Its frequency in normal
controls and in a larger sample of individuals with CMM in
Brazil should be evaluated to better determine its relevance
as a genetic risk factor for this disease.
Although potential environmental risk factors for the
occurrence of melanoma were identified in most of the
patients studied, our results indicate that germline mutations in
CDKN2A do have a role in the occurrence of CMM in
Southern Brazil. Several studies from different populations
have described the prevalence of CDKN2A germline mutations
in families with multiple CMM or pancreatic cancer (PC) cases,
and their results have been quite variable (Holland et al., 1995;
Flores et al., 1997; Platz et al., 1997; MacKie et al., 1998;
Soufir et al., 1998; Landi et al., 2004). This variability can be
related to different inclusion criteria used, with more strict
criteria, including a higher number of CMM and/or PC-affected
individuals per family, being usually associated with a higher
mutation prevalence. However, the number of affected
individuals (and degree of relationship among these) in a
given family is probably not the only determinant of mutation
prevalence. Other, population-specific genetic modifiers and
environmental risk factors may also have an effect on mutation
prevalence and thus, phenotypic recognition of melanoma
families in different populations (Bishop et al., 2002; de Snoo
et al., 2003; Begg et al., 2005; Berwick et al., 2006). The
relatively low mutation frequency observed in this study is not
unexpected, since relaxed inclusion criteria were used; other
studies of CDKN2A mutation prevalence using less strict
criteria in other populations have had similar results (Landi
et al., 2004; Eliason et al., 2006). Thus, our data reinforces that
genetic testing for hereditary predisposition to melanoma
should be offered preferentially to high-risk families with
either multiple primary CMM or X3 CMM or PC-affected
individuals (Hansen et al., 2004; Niendorf et al., 2006). Most
CMM diagnosed in early stages are surgically curable. In
advanced stages, however, mortality rates remain high even
after aggressive therapeutic interventions. Therefore, the
identification of genetically predisposed individuals is impor-
tant to assure proper referral and to optimize screening and
early diagnosis in this high-risk group.
MATERIALS AND METHODS
Study design and patient recruitment
This study was approved by the Ethics Committee of the participating
institutions and adhered to the Declaration of Helsinki Principles.
Patients were included after providing consent for the use of
their DNA samples. Individuals were recruited from in-hospital
dermatology clinics during 2000–2004 in the city of Porto Alegre, the
southernmost Brazilian capital. Patients included in the study had a
previous diagnosis of melanoma and at least one of the following: (a)
family history of melanoma; (b) family history of pancreatic cancer;
and (c) multiple primary melanomas in the same individual
regardless of family history. None of the index cases had a diagnosis
of pancreatic cancer. For inclusion criteria (a) and (b) we considered
the presence of affected first-, second-, and third-degree relatives as
a positive family history. These inclusion criteria were established
according to current evidence, which points to a CDKN2A mutation
frequency of 9–15% in patients with multiple primary melanomas
(Monzon et al., 1998; Puig et al., 2005), and 5–40% in families with
2 and 3 members affected with melanoma and/or PC (Hogg, 1998).
Age at diagnosis as an inclusion criterion alone (i.e., isolated CMM
case diagnosed at age 30 years) was not considered due to previous
evidence of very low CDKN2A mutation prevalence in such cases.
At inclusion, patients signed an IRB-approved informed consent, had
a dermatological examination and responded to a risk factor and
medical history questionnaire. A pedigree of at least three genera-
tions was recorded for each patient. Pathology reports were obtained
for all melanoma diagnoses in the probands; confirmation of
melanoma and pancreatic cancer and other cancer diagnoses in
patients’ relatives was obtained through medical records, death
certificates and/or pathology reports whenever possible. The
probability of a germline mutation in the CDKN2A gene was
estimated taking into account proband’s age at diagnosis, number of
primaries, and number of additional family primaries according to
the MELPREDICT model described by Niendorf et al. (2006).
Mutation analysis
Genomic DNA was extracted from peripheral blood by standard
procedures (Miller et al., 1998). Mutation analysis by sequencing of
the CDKN2A gene was performed as described previously (Liu et al.,
1999). In addition, each patient was screened for the CDK4
mutations R24H and R24C (Zuo et al., 1996), and for splice variants
in the p14ARF gene (Harland et al., 2005).
Statistical analysis
SPSS version 12.0 was used for data handling and statistical
analyses. For descriptive analysis, categorical variables were
described by their absolute and/or relative frequencies and
quantitative variables were expressed as mean7SD. For analytical
statistics, Student’s t-test for independent samples or analysis of
variance for more than two groups was used to compare symmetric
variables. The Mann–Whitney and Kruskal–Wallis tests were used
when comparing asymmetric variables in two or more groups,
respectively (nonparametric tests were used when appropriate due to
skewed distributions or small sample size). Categorical variables
were examined by w2 and multiple comparisons or Fisher’s exact
test, and the correlation coefficient of Spearman was used whenever
analysis included two quantitative variables.
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